Clovis Oncology, Inc. (CLVSQ) vs NeuroSense Therapeutics Ltd. (NRSN)

Clovis Oncology, Inc. and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Clovis Oncology, Inc. and NeuroSense Therapeutics Ltd. are of similar size ($14.2M and $14.0M). NeuroSense Therapeutics Ltd. has the higher net margin (0.00% vs −189.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, NeuroSense Therapeutics Ltd. leads on 7 and Clovis Oncology, Inc. on 4.

Valuation

Metric CLVSQ NRSN Biotechnology median
P/E n/m n/m 7.88
P/S 0.10 n/m 11.47
P/B n/m n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 3.08 n/m 10.73
Earnings yield (2,033.33%) (179.97%) (28.84%)
Free cash flow yield (1,412.40%) (339.53%) (23.03%)

Profitability

Metric CLVSQ NRSN Biotechnology median
Gross margin 72.21% — 65.16%
Operating margin (155.38%) 0.00% 0.00%
Net margin (189.37%) 0.00% 0.00%
Free cash flow margin (132.19%) 0.00% 0.00%
Return on equity 78.31% 0.00% (57.72%)
Return on assets (58.94%) 0.00% (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CLVSQ NRSN Biotechnology median
Revenue growth (TTM) (14.78%) — 5.64%
EPS growth (last fiscal year) 47.72% 20.45% —
Revenue growth, 5-year CAGR 352.98% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CLVSQ NRSN Biotechnology median
Debt to equity (1.09) 0.00 0.00
Current ratio 0.14 0.71 4.73
Net debt to EBITDA (2.21) 0.01 0.96

Dividend

Metric CLVSQ NRSN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CLVSQ NRSN Biotechnology median
Market cap 14.23m 14.04m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack